Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783693 | 0.96 | DRD2 (0.47) | DRD2DRD4DRD3ACHEHTR2A | |
| SCHEMBL5781460 | 0.93 | DRD2 (0.55) | DRD2DRD4DRD3ACHEHRH3 | |
| SCHEMBL5781625 | 0.86 | DRD2 (0.48) | DRD2DRD4DRD3ACHEHRH3 | |
| Oxalic Acid SCHEMBL5782852 | 0.85 | DRD2 (0.46) | DRD2DRD4DRD3ACHESIGMAR1 | |
| SCHEMBL5778870 | 0.85 | ATM (0.61) | SIGMAR1ATMALDH1A1 | |
| SCHEMBL5782055 | 0.82 | CHRM2 (0.38) | ACHESIGMAR1 | |
| SCHEMBL5781924 | 0.81 | ACHE (0.43) | DRD2DRD4DRD3ACHEHRH3 | |
| SCHEMBL5780975 | 0.81 | MPO (0.46) | DRD2DRD4DRD3ACHESIGMAR1 | |
| SCHEMBL5778729 | 0.81 | ACHE (0.49) | DRD2DRD4DRD3ACHEHTR2C | |
| Hydrochloric Acid SCHEMBL6890167 | 0.81 | CCR3 (0.45) | DRD2DRD4DRD3ACHEHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| CN-1395575-A | Novel piperidine compounds and drugs containing the same | EISAI CO LTD (JP) | 2003-02-05 | — | — | CN | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | DRD2 53/4885DRD4 117/4885DRD3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.